Driehaus Capital discloses 6.64% stake in Definium Therapeutics (DFTX)
Rhea-AI Filing Summary
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of Definium Therapeutics, Inc. common stock. Driehaus has shared voting and dispositive power over 6,537,202 shares, representing 6.64% of the company’s common stock as of the event date.
The shares are held in numerous fully discretionary client accounts managed by Driehaus, which reports potential voting and dispositive power, while clients generally do not hold more than 5% of the class individually. Driehaus states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Definium Therapeutics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Definium Therapeutics (DFTX) does Driehaus Capital Management own?
Driehaus Capital Management reports beneficial ownership of 6.64% of Definium Therapeutics’ common stock. This corresponds to 6,537,202 shares over which it has shared voting and dispositive power through client accounts it manages on a fully discretionary basis.
Does Driehaus Capital Management seek to influence control of Definium Therapeutics (DFTX)?
Driehaus Capital Management states the securities were acquired and are held in the ordinary course of business. It certifies they were not acquired for the purpose of changing or influencing control of Definium Therapeutics and are not held in connection with any such control-related transaction.
When was Driehaus’s Definium Therapeutics (DFTX) ownership position measured?
The reported beneficial ownership position of Driehaus in Definium Therapeutics is tied to an event date of December 31, 2025. As of that date, Driehaus held shared voting and dispositive power over 6,537,202 common shares, representing 6.64% of the outstanding class.